Key result
Cardiomyocyte-specific ablation of p53 was not sufficient to prevent Doxorubicin-induced myocardial ROS/RNS generation, apoptosis, interstitial fibrosis, and perivascular fibrosis in mice.
Why the study?
Does cardiomyocyte-specific ablation of p53 prevent doxorubicin-induced cardiac fibrosis and apoptosis in mice?
Does cardiomyocyte-specific ablation of p53 prevent doxorubicin-induced cardiac fibrosis and apoptosis in mice?
Cardiomyocyte-specific ablation of p53 does not prevent doxorubicin-induced myocardial damage, indicating the involvement of p53-independent apoptotic pathways.
Answers are grounded in this paper and cite their sources.
Cardiomyocyte p53 ablation fails to block doxorubicin cardiotoxicity in mice; hypothesis-generating for p53-independent pathways and should not yet guide therapy.
Doxorubicin (Dox) is an anthracycline used to effectively treat several forms of cancer. Unfortunately, the use of Dox is limited due to its association with cardiovascular complications which are manifested as acute and chronic cardiotoxicity. The pathophysiological mechanism of Dox induced cardiotoxicity appears to involve increased expression of the tumor suppressor protein p53 in cardiomyocytes, followed by cellular apoptosis. It is not known whether downregulation of p53 expression in cardiomyocytes would result in decreased rates of myocardial fibrosis which occurs in response to cardiomyocyte loss. Further, it is not known whether Dox can induce perivascular necrosis and associated fibrosis in the heart. In this study we measured the effects of acute Dox treatment on myocardial and perivascular apoptosis and fibrosis in a conditional knockout (CKO) mouse model system which harbours inactive p53 alleles specifically in cardiomyocytes. CKO mice treated with a single dose of Dox (20 mg/kg), did not display lower levels of myocardial apoptosis or reactive oxygen and nitrogen species (ROS/RNS) compared to control mice with intact p53 alleles. Interestingly, CKO mice also displayed higher levels of interstitial and perivascular fibrosis compared to controls 3 or 7 days after Dox treatment. Additionally, the decrease in levels of the microtubule protein α-tubulin, which occurs in response to Dox treatment, was not prevented in CKO mice. Overall, these results indicate that selective loss of p53 in cardiomyocytes is not sufficient to prevent Dox induced myocardial ROS/RNS generation, apoptosis, interstitial fibrosis and perivascular fibrosis. Further, these results support a role for p53 independent apoptotic pathways leading to Dox induced myocardial damage and highlight the importance of vascular lesions in Dox induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Feridooni et al. (2011) studied Doxorubicin-induced cardiotoxicity. Cardiomyocyte-specific ablation of p53 vs. Control mice with intact p53 alleles was evaluated on Myocardial and perivascular apoptosis and fibrosis, and ROS/RNS levels. Cardiomyocyte-specific ablation of p53 was not sufficient to prevent Doxorubicin-induced myocardial ROS/RNS generation, apoptosis, interstitial fibrosis, and perivascular fibrosis in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: